Vallon shares fall nearly 70% after the new drug for ADHD failed
- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
Vallon shares fall nearly 70% after the new drug for ADHD failed
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
Vallon shares fall nearly 70% after the new drug for ADHD failed.
On March 21, Vallon Pharmaceuticals announced that the pivotal study, code-named SEAL, which evaluated the company’s proprietary immediate-release (IR) dextroamphetamine (dexamphetamine) abuse-resistant formulation ADAIR, failed to meet its primary endpoint for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Affected by the news, the company’s stock price fell nearly 70%.
ADAIR is prepared for inhalation by a pharmacist using a multi-step technique approved by the US FDA in a specialized laboratory. Designed to prevent people from consuming dextroamphetamine through crushing, snorting, or other non-oral routes, resulting in a greater “high”. Dextroamphetamine has been used clinically for more than 50 years and is the first class of psychotropic drugs. It has the same active ingredient as FDA-approved products like Adderall ® , Dexedrine ® and Vyvanse ® .
The SEAL study enrolled 55 subjects, of whom 53 completed the study and 52 were included in the final analysis. This study involved a four-way crossover design to evaluate the abuse tendency, pharmacokinetics, safety and tolerance of professionally administered intranasal ADAIR 30 mg vs crushed intranasal dexamphetamine sulfate vs oral ADAIR vs placebo acceptability.
The study did not meet its primary endpoint, Emax Drug Liking (maximum drug likability for subjects). ADAIR scores were similar to those observed in earlier proof-of-concept studies, however, scores for dextroamphetamine in the control group were not as high as expected, inconsistent with what was seen in previous studies, and thus lacked statistical significance.
However, the study met all secondary pharmacodynamic endpoints, with ADAIR scores significantly lower than the comparator dexamphetamine sulfate for 12-hour assessment and overall drug preference at 24 hours post-dose, p<.0001 and p=0.024, respectively.
Drug preference was measured at 12 time points from 15 minutes to 24 hours after dosing. Post-hoc analysis showed that the average drug favorability of intranasal ADAIR was lower than that of the control drug dexamphetamine sulfate at each time point from 15 minutes to 24 hours after administration, and statistically significant at each time point from 15 minutes to 6 hours after administration. significance.
DAIR was generally well tolerated, with a safety profile consistent with the known effects of amphetamines in all active treatment groups, with no unexpected adverse events reported.
During the study period, no serious adverse events (SAEs) were reported in any of the treatment groups, and there were no discontinuation events due to adverse events.
Vallon shares fall nearly 70% after the new drug for ADHD failed
(source:internet, reference only)
Disclaimer of medicaltrend.org
